SUNWELS Co.,Ltd. (JP:9229)
:9229
Want to see JP:9229 full AI Analyst Report?
Top Page
SUNWELS Co.,Ltd.
(9229)
Select Model
Select Model
Rating:44Neutral
Price Target:
¥113.00
▼(-67.06% Downside)
Action:Upgraded
Date:06/26/26
The score is driven primarily by weak financial performance (profitability breakdown, rising leverage, and negative operating/free cash flow). Technical indicators also point to ongoing bearish momentum with the price far below key moving averages. Valuation provides limited support because losses make the negative P/E difficult to interpret and no dividend yield is available.
Positive Factors
Revenue Growth Trend
Sunwels showed multi-year revenue expansion (strong 2021–2024 growth and a re-acceleration to ~4.7% in FY2026). Persistent top-line growth across cycles indicates sustained demand for its care services, supporting utilization gains, scale benefits, and the potential to restore margins over a medium-term horizon.
Negative Factors
Margin Deterioration
Gross margin compression from ~30% to under 10% and a swing to an operating loss signal structural margin pressure. Such deterioration reduces internal funding for improvements or expansions, weakens profitability resilience, and makes margin recovery dependent on sustained cost control or pricing power over many quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Trend
Sunwels showed multi-year revenue expansion (strong 2021–2024 growth and a re-acceleration to ~4.7% in FY2026). Persistent top-line growth across cycles indicates sustained demand for its care services, supporting utilization gains, scale benefits, and the potential to restore margins over a medium-term horizon.
Read all positive factors
SUNWELS Co.,Ltd. (9229) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.16B
Dividend YieldN/A
Average Volume (3M)115.88K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth6.19%
EPS Growth-80.97%
CountryJP
Employees2,435
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-54.63
Shares Outstanding35,220,000
10 Day Avg. Volume157,720
30 Day Avg. Volume115,876
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.15
Price to Sales (P/S)0.28
P/FCF Ratio-5.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-27.7
Revenue Forecast (FY)¥32.00B
SUNWELS Co.,Ltd. Business Overview & Revenue Model
Company Description
Sunwels Co., Ltd. primarily delivers nursing care services, with its operations prominently featuring the "PD house" model. The company runs specialized residential facilities for seniors diagnosed with Parkinson's disease and also manages a Kaats...
How the Company Makes Money
SUNWELS primarily earns revenue by operating care service facilities and providing long-term care services, receiving payments tied to service usage. Key revenue streams likely include fees and reimbursements associated with providing care under J...
SUNWELS Co.,Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
24
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.86B | 28.14B | 26.50B | 20.11B | 13.24B | 8.17B |
| Gross Profit | 3.99B | 2.76B | 4.89B | 5.13B | 3.24B | 1.60B |
| EBITDA | 986.00M | 1.88B | 1.88B | 3.15B | 1.52B | 573.94M |
| Net Income | -1.77B | -1.66B | -925.00M | 802.00M | 303.60M | 10.65M |
Balance Sheet | ||||||
| Total Assets | 42.22B | 45.63B | 39.44B | 31.74B | 19.30B | 9.10B |
| Cash, Cash Equivalents and Short-Term Investments | 3.62B | 4.09B | 5.64B | 3.31B | 2.61B | 814.76M |
| Total Debt | 26.35B | 29.11B | 22.49B | 20.11B | 11.20B | 6.60B |
| Total Liabilities | 34.32B | 38.66B | 30.82B | 26.54B | 14.69B | 8.52B |
| Stockholders Equity | 7.89B | 6.97B | 8.62B | 5.20B | 4.61B | 580.80M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.50B | -2.32B | -2.93B | -740.86M | -73.95M |
| Operating Cash Flow | 0.00 | -332.00M | 1.88B | 2.56B | 1.14B | 378.19M |
| Investing Cash Flow | 0.00 | -1.27B | -4.40B | -5.66B | -2.04B | -633.05M |
| Financing Cash Flow | 0.00 | 62.00M | 4.84B | 3.80B | 2.70B | 573.26M |
SUNWELS Co.,Ltd. Technical Analysis
Negative
343.00
Price Trends
178.70
Negative
225.17
Negative
366.66
Negative
Market Momentum
-17.68
Positive
29.52
Positive
18.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9229, the sentiment is Negative. The current price of 343 is above the 20-day moving average (MA) of 141.35, above the 50-day MA of 178.70, and below the 200-day MA of 366.66, indicating a bearish trend. The MACD of -17.68 indicates Positive momentum. The RSI at 29.52 is Positive, neither overbought nor oversold. The STOCH value of 18.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9229.
SUNWELS Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥2.89B | 6.50 | ― | 2.82% | 5.16% | 22.96% | |
68 Neutral | ¥105.07B | 27.17 | ― | 2.47% | 2.70% | -5.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥5.52B | 52.63 | ― | 4.07% | 4.85% | -85.27% | |
51 Neutral | ¥2.37B | 20.57 | ― | 2.56% | -6.54% | -69.23% | |
46 Neutral | ¥4.47B | 14.69 | ― | 1.41% | 16.83% | -45.33% | |
44 Neutral | ¥4.16B | -2.31 | ― | ― | 6.19% | -80.97% |
* Healthcare Sector Average
JP:9229
SUNWELS Co.,Ltd.
118.00
-479.00
-80.23%
JP:2373
Care Twentyone Corporation
410.00
18.26
4.66%
JP:2425
Care Service Co., Ltd.
624.00
-156.58
-20.06%
JP:6197
Solasto Corp.
1,109.00
701.17
171.93%
JP:7061
Japan Hospice Holdings Inc.
527.00
-536.07
-50.43%
JP:9220
FB CARE SERVICE CO.,LTD.
1,185.00
159.09
15.51%
SUNWELS Co.,Ltd. Corporate Events
SUNWELS Details Transactions and Governance Measures Involving Controlling Shareholder
Jun 23, 2026
SUNWELS Co., Ltd. disclosed matters related to its controlling shareholder, President and Representative Director Ryotatsu Nawashiro, who holds a combined 53.70% voting interest through direct and indirect ownership. The company detailed recent tr...
Sunwels Replaces President to Strengthen Governance and Rebuild Stakeholder Trust
May 26, 2026
Sunwels Co., Ltd. has announced a leadership transition in which outside director Toshihiko Atarashi will become president and representative director, replacing incumbent chief executive Ryotatsu Nawashiro, who will remain on the board as a direc...
SUNWELS Completes Recurrence Prevention Overhaul in Home-Visit Nursing Operations
May 26, 2026
SUNWELS Co., Ltd. announced that it has largely completed the implementation of recurrence prevention measures for its home-visit nursing and care operations, moving from a remediation phase into continuous operation and improvement of new control...
SUNWELS Corrects Per-Share Data in FY2026 Non-Consolidated Results
May 13, 2026
SUNWELS Co., Ltd. announced that it has corrected errors in its previously released non-consolidated financial results for the fiscal year ended March 31, 2026, prepared under Japanese GAAP. The revisions affect per-share indicators, including net...
SUNWELS Scraps Year-End Dividend After Posting ¥1.66 Billion Net Loss
May 12, 2026
SUNWELS Co., Ltd. has announced that its board of directors resolved not to pay a year-end dividend for the fiscal year ended March 31, 2026, maintaining a dividend per share of zero yen as in the previous year. The decision follows the company...
Sunwels outlines FY March 2026 results and care-focused growth strategy
May 12, 2026
Sunwels Co., Ltd. released financial highlights for the fiscal year ending March 2026 alongside an overview of its business profile centered on healthcare and caregiving services. The company emphasized initiatives like its specialized ‘PD H...
SUNWELS Swings to Loss Despite Higher Sales, Signals Gradual Earnings Recovery
May 12, 2026
SUNWELS Co., Ltd. reported a 6.2% rise in net sales to ¥28.1 billion for the year ended March 31, 2026, but swung to an operating loss of ¥1.2 billion and an ordinary loss of ¥2.2 billion, resulting in a net loss of ¥1.7 billio...
SUNWELS Faces Added TSE Supervision as It Seeks Shift to Standard Market
Apr 30, 2026
SUNWELS Co., Ltd. reported that the Tokyo Stock Exchange will add a new reason for designating its shares as Securities Under Supervision (Examination) from May 1, 2026, linked to a prior violation of a written pledge and its ongoing preliminary a...
SUNWELS Defers Loan Principal and Redirects Equity Proceeds to Working Capital
Apr 21, 2026
SUNWELS has secured agreement from nine financial institutions to defer principal repayments totaling ¥574 million falling due between April 30 and September 30, 2026, while continuing to pay interest. The company positions the year to March ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.